ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Gwadz RW, Carter R, Green I, 1979. Gamete vaccines and transmission-blocking immunity in malaria. Bull World Health Organ 57 (Suppl 1):175–180.
-
2
Kaslow DC, 1996. Transmission-blocking vaccines. Hoffman SL, ed. Malaria Vaccine Development. Washington, DC: American Society for Microbiology Press, 181–228.
-
3
Carter R, Mendis KN, Miller LH, Molineaux L, Saul A, 2000. Malaria transmission-blocking vaccines: how can their development be supported? Nat Med 6 :241–244.
-
4
Stowers A, Carter R, 2000. Current development in malaria transmission-blocking vaccines. Expert Opin Biol Ther 1 :619–628.
-
5
Tomas AM, Margos G, Dimopoulos G, van Lin LH, de Konigpward TF, Sinha R, Lupetti P, Beetsma AL, Rodriguez MC, Karras M, Hager A, Mendoza J, Butcher GA, Kafatos F, Janse CJ, Waters AP, Sinden RE, 2001. P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions. EMBO J 20 :3975–3983.
-
6
Kaslow DC, Bathurst JC, Lensen T, Ponnudurai T, Barr PJ, Keister DB, 1994. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect Immun 62 :5576–5580.
-
7
Hisaeda H, Stowers A, Tsuboi T, Collins WE, Sattabongkot JS, Suwanabun N, Torii M, Kaslow DC, 2000. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun 66 :6618–6623.
-
8
Hisaeda H, Collins WE, Saul A, Stowers AW, 2002. Antibodies to Plasmodium vivax transmission-blocking vaccine do not show synergism. Vaccine 20 :763–770.
-
9
Kongkasuriyachai D, Bartels-Andrews L, Stowers A, Collins WE, Sullivan J, Sattabonkot JS, Torii M, Tsuboi T, Kumar N, 2004. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy. Vaccine 22 :3205–3213.
-
10
Duffy PE, Kaslow DC, 1997. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as Plasmodium falciparum malaria transmission-blocking vaccine. Infect Immun 65 :74–76.
-
11
Tsuboi T, Cao YM, Hitsumoto Y, Yanagi T, Kanabara H, Torii M, 1997. Two antigens on zygotes and ookinetes of Plasmodium yoelii and Plasmodium berghei that are distinct targets of transmission-blocking immunity. Infect Immun 65 :2260–2264.
-
12
Tsuboi T, Kaslow D, Gozar M, Tachibana M, Cao Y, Torii M, 1998. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol Med 4 :772–782.
-
13
Miles AP, Zhang Y, Saul A, Stowers AW, 2002. Large-scale purification and characterization of malaria vaccine candidate antigen Pvs25H for use in clinical trials. Protein Expr Purif 25 :87–96.
-
14
Collins WE, Contacos PG, Krotoski WA, Howard WA, 1972. Transmission of four Central American strains of Plasmodium vivax. J Parasitol 58 :332–335.
-
15
Malkin EM, Dubin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A, 2005. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23 :3131–3138.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 0 | 0 | 0 |
| Full Text Views | 233 | 98 | 0 |
| PDF Downloads | 45 | 27 | 0 |
ASSESSMENT OF TRANSMISSION-BLOCKING ACTIVITY OF CANDIDATE Pvs25 VACCINE USING GAMETOCYTES FROM CHIMPANZEES
Macaca mulatta monkeys were immunized with the candidate transmission-blocking vaccine against Plasmodium vivax, Pvs25, combined with alum or Montanide ISA 720. Efficacy was measured by combining post-immunization sera with gametocytes obtained from infections induced in chimpanzees using membrane-feeding techniques. The results indicate that immunization of M. mulatta monkeys with Pvs25 and Montanide ISA 720 was more effective than with alum in efficacy and resulted in the maintenance of a lasting transmission-blocking immunity to P. vivax. This was evident two weeks after the second immunization, and more strongly demonstrable 62 and 152 days after the second immunization. This transmission-blocking activity was strongly reinforced by a third immunization given 181 days after the primary immunization, as measured three weeks later by indirect membrane feeding. The use of gametocytes of P. vivax derived from infections induced in chimpanzees can contribute to the selection of appropriate constructs, formulations, and immunization regimens for the development of effective transmission-blocking vaccines.